Burning Rock Biotech (BNR) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Burning Rock Biotech (BNR) has outperformed TriSalus Life Sciences (TLSI) over the past year, gaining 80.5% versus a loss of 8.1%. Over five years, TLSI leads with a -59.0% price change compared with -89.2% for BNR. TriSalus Life Sciences is the larger company by market cap ($250.0 million vs $163.4 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNR | TLSI |
|---|---|---|
| Share price | $15.49 | $4.06 |
| Market cap | $163.36M | $249.99M |
| 1-day change | +3.27% | -1.69% |
| YTD return | -23.13% | -41.83% |
| 1-year return | +80.54% | -8.14% |
| 5-year return | -89.21% | -58.99% |
| EPS (TTM) | $-0.81 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $41.72 | $7.95 |
| 52-week low | $6.79 | $2.20 |
| Distance from 52-week high | -62.87% | -48.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +156.16% |
| Average volume | 28.59K | 276.02K |
| Shares outstanding | 8.81M | 61.57M |
| Employees | 667 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNR has outperformed TLSI by 88.7 percentage points over the past year.
About Burning Rock Biotech
BNR stock →Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Health Care · Medical Specialities · 667 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
BNR vs TLSI FAQ
Which is bigger, Burning Rock Biotech or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $249.99M compared with $163.36M for Burning Rock Biotech (BNR).
Which stock has performed better over the past year, BNR or TLSI?
BNR returned +80.54% over the past 12 months, compared with -8.14% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are Burning Rock Biotech and TriSalus Life Sciences in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.